ProGen Biologics is a technology company with core focus on developing solutions for analysis of aberrant humoral responses. Company sells ELISA kits based on receptor capture (Proceptor™) to measure CICs and complement products bound to CICs. Measuring complement bound to CICs in nanogram amount provides an accurate and sensitive status of immune activation.

To facilitate the biomarker discovery, company provides receptor-based technology for purifying CIC from disease plasma/serum/synovial fluid. Purified CICs can then be analyzed using 2D SDS-PAGE or LC-MS/MS for antigen identification. Company provides services for the purification of CIC that can be subjected to 2D SDS-PAGE analysis, LC-MS/MS analysis, and measurement of complement bound to CIC's. Company support assay development for antigenicity assessment of bio-therapeutics.

Company supports the measurement of the lymphocyte population that express low affinity receptors such as Fc⋎RIIa and Fc⋎RIIIa. Recently, it has been shown that Fc⋎RIIa marks those cells that are enriched with HIV-1 provirus. Fc⋎RIIIa mediated cosignaling triggers differentiation of human naïve CD4+ T cells. This signal triggers relocation of nucleic-acid sensing toll-like receptors to cell surface, where they can recognize modified self-nucleic acids [1, 2]